Sign In
NASDAQ:BLRX
BioLineRx Ltd. Stock Earnings Reports
$3.58
+0.160 (+4.68%)
At Close: Mar 21, 2025
BioLineRx Ltd. Earnings Calls
Q4 2024
(Upcoming)
| Release date | Mar 25, 2025 |
| EPS estimate | -$4.20 |
| EPS actual | - |
| Revenue estimate | 7.718M |
| Revenue actual | - |
| Expected change | +/- 12.26% |
Q3 2024
Missed
-$2.80 (-5,500.00%)
| Release date | Nov 25, 2024 |
| EPS estimate | -$0.0500 |
| EPS actual | -$2.80 |
| EPS Surprise | -5,500.00% |
| Revenue estimate | 5.231M |
| Revenue actual | 4.943M |
| Revenue Surprise | -5.51% |
Q2 2024
Beat
$0.400 (385.71%)
| Release date | Aug 15, 2024 |
| EPS estimate | -$0.140 |
| EPS actual | $0.400 |
| EPS Surprise | 385.71% |
| Revenue estimate | 3.93M |
| Revenue actual | 5.393M |
| Revenue Surprise | 37.23% |
Q1 2024
Beat
-$0.0100 (96.55%)
| Release date | May 28, 2024 |
| EPS estimate | -$0.290 |
| EPS actual | -$0.0100 |
| EPS Surprise | 96.55% |
| Revenue estimate | 6.8M |
| Revenue actual | 6.855M |
| Revenue Surprise | 0.81% |
Last 4 Quarters for BioLineRx Ltd.
Below you can see how BLRX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Beat
| Release date | May 28, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $0.719 |
| EPS estimate | -$0.290 |
| EPS actual | -$0.0100 |
| EPS surprise | 96.55% |
| Date | Price |
|---|---|
| May 21, 2024 | $0.623 |
| May 22, 2024 | $0.620 |
| May 23, 2024 | $0.605 |
| May 24, 2024 | $0.685 |
| May 28, 2024 | $0.719 |
| May 29, 2024 | $0.690 |
| May 30, 2024 | $0.82 |
| May 31, 2024 | $0.746 |
| Jun 03, 2024 | $0.734 |
| 4 days before | 15.43% |
| 4 days after | 2.09% |
| On release day | -4.03% |
| Change in period | 17.84% |
Q2 2024
Beat
| Release date | Aug 15, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $0.678 |
| EPS estimate | -$0.140 |
| EPS actual | $0.400 |
| EPS surprise | 385.71% |
| Date | Price |
|---|---|
| Aug 09, 2024 | $0.739 |
| Aug 12, 2024 | $0.790 |
| Aug 13, 2024 | $0.771 |
| Aug 14, 2024 | $0.775 |
| Aug 15, 2024 | $0.678 |
| Aug 16, 2024 | $0.739 |
| Aug 19, 2024 | $0.790 |
| Aug 20, 2024 | $0.746 |
| Aug 21, 2024 | $0.740 |
| 4 days before | -8.19% |
| 4 days after | 9.10% |
| On release day | 8.88% |
| Change in period | 0.162% |
Q3 2024
Missed
| Release date | Nov 25, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $0.272 |
| EPS estimate | -$0.0500 |
| EPS actual | -$2.80 |
| EPS surprise | -5,500.00% |
| Date | Price |
|---|---|
| Nov 19, 2024 | $0.536 |
| Nov 20, 2024 | $0.545 |
| Nov 21, 2024 | $0.323 |
| Nov 22, 2024 | $0.278 |
| Nov 25, 2024 | $0.272 |
| Nov 26, 2024 | $0.276 |
| Nov 27, 2024 | $0.287 |
| Nov 29, 2024 | $0.297 |
| Dec 02, 2024 | $0.291 |
| 4 days before | -49.35% |
| 4 days after | 7.25% |
| On release day | 1.66% |
| Change in period | -45.67% |
Q4 2024
(Upcoming)
| Release date | Mar 25, 2025 |
| Fiscal end date | Dec 30, 2024 |
| Price on release | - |
| EPS estimate | -$4.20 |
| EPS actual | - |
| Date | Price |
|---|---|
| Mar 17, 2025 | $3.22 |
| Mar 18, 2025 | $3.18 |
| Mar 19, 2025 | $3.39 |
| Mar 20, 2025 | $3.42 |
| Mar 21, 2025 | $3.58 |
BioLineRx Ltd. Earnings Call Transcript Summary of Q3 2024
- Potential Milestones: Up to $87 million based on commercial performance.
- Royalties: Between 18% and 23% on net sales.
- Focus on Cash Flow: A further equity investment of $9 million from Highbridge Capital allows for significant debt repayment with BlackRock, enhancing cash flow.
Financial Performance
- Revenue: Total Q3 2024 revenue was $4.9 million, compared to none in Q3 2023. This includes:
- $3.2 million from Gloria Biosciences licensing.
- $1.7 million from APHEXDA sales.
- Net Loss: Reduced net loss of $5.8 million in Q3 2024, down from $16 million in the same period last year.
- Cash Position: Cash and equivalents totaled $29.2 million as of September 30, 2024, expected to cushion operations into 2026 post-debt reorganization.
Operational Changes
- Commercial Strategy: BioLineRx is transitioning from U.S. commercialization to focus on R&D, reducing annual cash burn by over 70% by January 1, 2025.
- Streamlining: The reduction includes shutting down U.S. commercial operations while retaining a smaller organization focused on drug development in Israel.
Clinical Development
- Motixafortide in PDAC: Continuing to develop motixafortide for pancreatic cancer through collaborations, with a randomized Phase 2b trial underway, expecting interim results in 2026.
- Additional Asset Evaluation: Plans to explore and potentially in-license two early-stage assets in oncology and rare diseases by 2025 and 2026.
Market Potential
- APHEXDA Adoption: Achieved over 10% market share in U.S. CXCR4 inhibitor usage, with growing sales traction in transplant centers, critical for expanding APHEXDA's commercial success.
Conclusion
- Future Outlook: BioLineRx aims to create long-term shareholder value while committing to clinical development of therapies that address significant medical needs, particularly in cancer and rare diseases.
Key Takeaways for Investors
- Strong financial maneuvers with licensing agreements and debt repayment provide stability.
- Transition to a focused R&D player with reduced operational costs should foster growth in clinical programs and new asset acquisitions.
- Promising data from ongoing studies and solidifying market presence with APHEXDA cultivate potential for increased revenue and strategic partnerships in the near future.
BioLineRx Ltd. Earnings History
Earnings Calendar
FAQ
When is the earnings report for BLRX?
BioLineRx Ltd. (BLRX) has scheduled its earnings report for Mar 25, 2025 before the markets open.
What is the BLRX price-to-earnings (P/E) ratio?
BLRX P/E ratio as of Mar 21, 2025 (TTM) is -0.292.
What is the BLRX EPS forecast?
The forecasted EPS (Earnings Per Share) for BioLineRx Ltd. (BLRX) for the first fiscal quarter 2024 is -$4.20.
What are BioLineRx Ltd.'s retained earnings?
On its balance sheet, BioLineRx Ltd. reported retained earnings of $4.94 million for the latest quarter ending Sep 30, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
